The biomedical service division of the Huangpu market supervision bureau was recently recognized as an advanced collective of national medical products supervision system.
From 2020 to 2021, Huangpu examined the quality system of key medical products manufacturers 86 times, pointed out 241 problems, and proposed 92 suggestions relying on risk evaluation and data analysis. Third-party institutions were also invited to take part in the examination process to ensure adequate manpower and professionalism.
Meanwhile, Huangpu took the lead in the launch of coordinated supervision for medical products by provincial and district authorities back in August 2020. The Huangpu market supervision bureau has strengthened the information sharing and complemented the advantages with the Guangdong Medical Products Administration in administrative approval and supervision of medicines.
The production base of Huangpu biotechnology company BeiGene.
To offer one-stop services for the application of new medicines, Huangpu established the first dedicated service institution in Guangdong, which consists of experts with working experience in the National Medical Products Administration, technological talents, and good manufacturing practice (GMP) inspectors.
Biomedicine is a pillar industry in Huangpu, where there was an increase of 23 pharmaceutical enterprises over the past two years. The district is now home to 63 pharmaceutical enterprises, accounting for 42.9 percent of Guangzhou's total.